Dementia therapy: genuine breakthrough, or another false dawn?
For decades, scientists have trodden a largely futile path in the unsuccessful search for treatments of dementia, but a new study suggests that we may finally be turning the corner.
A research group, based at the Medical Research Council Toxicology unit of the University of Leicester, has uncovered a chemical with the ability to prevent the death of brain tissue in neurodegenerative disease.
The collective sigh of the public at news of this type is almost audible, and that’s partly understandable. The popular press (and specifically a certain British contingent) churn out such stories on such a regular basis that, for each groundbreaking ‘dementia treatment study’, it becomes difficult to stifle a sceptical yawn.
Indeed, a search on the Daily Mail website for ‘Alzheimer’s cure’ returns a remarkable 292 articles. Despite this deluge of promising studies, drugs approaching a cure are still conspicuously absent. Why could this study, published this week in Science Translational Medicine, be any different?
An answer lies in the type of process targeted by the chemical used by the research team. Instead of focusing on features specific to each disease, they manipulated a cell defence pathway commonly activated in a range of neurodegenerative diseases, which shuts down protein production in reaction to the accumulation of defective, ‘misfolded’ proteins.
As the long-term activation of this system effectively causes neurons to starve and die, repetition of the process in many cells across the brain can progressively corrupt a range of functions, including motor function and memory.
However, by blocking the action of an enzyme called PERK in the defence process, the compound used by the researchers was able to prevent the death of brain tissue in mice that would otherwise have shown severe cognitive deficits resulting from an aggressive form of prion disease.
As lead researcher Professor Giovanna Mallucci put it: “It was extraordinary – they were absolutely fine.
“[The] compound has completely prevented neurodegeneration, and that’s a first.”
Other experts in the field mirrored Mallucci’s positive comments but urged for caution in interpreting the results, emphasizing the need for this preliminary work to be repeated in all models of neurodegenerative disease. If a success, the subsequent development and testing of drugs based on the compound could take at least a decade, while the significant weight loss and mild diabetes caused by the compound also demonstrates the need for side effects to be minimized. Despite these reservations, the resonance of this investigation throughout the global scientific community is a good indicator of its therapeutic potential; few recent studies have generated so much interest.
Indeed, Professor Roger Morris (King’s College London) predicted the work will represent a landmark in the field, saying: “This finding, I suspect, will be judged by history as a turning point in the search for medicines to control and prevent Alzheimer’s disease.” Such a forecast indicates a degree of anticipation seen very rarely in a field where the scientists themselves are often more sceptical than most.
Photograph: Reigh LeBlanc

